Please use this identifier to cite or link to this item:
|Title:||The effect of long-term alendronate treatment on cortical thickness of the proximal femur|
Quang V. Ton
John P. Kleimeyer
Joseph M. Lane
Hospital for Special Surgery - New York
Department of Internal Medicine
Weill Cornell Medical College
|Citation:||Clinical Orthopaedics and Related Research. Vol.470, No.1 (2012), 291-298|
|Abstract:||Background One of the radiographic hallmarks in patients with atypical femoral insufficiency fractures after prolonged bisphosphonate treatment is generalized cortical hypertrophy. Whether cortical thickening in the proximal femur is caused by long-term alendronate therapy, however, remains unknown. Questions/purposes We asked whether long-term alendronate use of 5 years or more results in progressive thickening of the subtrochanteric femoral cortices. Patients and Methods We retrospectively evaluated changes in cortical thickness and cortical thickness ratio (ratio of cortical to femoral shaft diameter) at the subtrochanteric region of the proximal femur in baseline and latest hip dual-energy xray absorptiometry (DXA) scans of 131 patients. The mean followup was 7.3 years. Patients were divided into two groups: control (no history of alendronate, 45 patients) and alendronate (history of alendronate C 5 years, 86 patients). We determined cortical thickness and cortical thickness ratio at 3.5 and 4.0 cm below the tip of the greater trochanter, representing the subtrochanteric region. Results After a minimum of 5 years followup, mean cortical thickness decreased approximately 3% in the alendronate and control groups. The cortical thickness at the subtrochanteric femoral region changed less than 1 mm in greater than 90% of the patients with long-term alendronate treatment. We observed no differences in mean changes of cortical thickness and percent changes of cortical thickness between the two groups. Conclusions Long-term alendronate treatment did not appear to cause thickened femoral cortices within the detection limits of our method. This finding contrasts with the notion that long-term alendronate treatment leads to generalized cortical thickening. Level of Evidence Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.© The Association of Bone and Joint Surgeons® 2011.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.